New Energy Capital is an investment franchise focused on clean energy and infrastructure assets, investing across the capital structures of clean energy infrastructure projects and companies. self-described.

New Energy Capital

New Access Capital is an investment and financial advisory firm in China, self-described as elite and specializing in growth-stage investing.

New Access Capital

LEMARRC is a private global investment firm that supports the growth of companies internationally.

LEMARRC

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Metric
Company Name	New Energy Capital	New Access Capital	LEMARRC	Transgene SA
Symbol				TNG
MSH ID	COM:NEWENERGYCAPITAL	CN:COM:NEWACCESS	COM:LEMARRC	FR:TRANSGENE
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Financial Services & Finance	Financial Services & Finance	Financial Services & Finance	Healthcare
Industry	Investment Management	Investment Management	Investment Management	Biotechnology
Country	US	CN	DE	FR
Stage
Employee Count	1			141
Website	newenergycapital.com	newaccess.com.cn/english	lemarrc.com	transgene.fr
LinkedIn		new-access-capital	lemarrc	transgene
Founders

Metric
Market Cap				112.77M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue				1.25M
Revenue (LTM)
Revenue (NTM)
Gross Profit				1.25M
EBITDA				-35.69M
Operating Income				-37.38M
Net Income				-23.58M
EPS				-0.23
Diluted EPS				-0.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				-3.78
Operating Profit Margin				-7.53
EBITDA Margin				-28.54
Net Profit Margin				-5.20
Return on Equity				-1.26
Return on Assets				-0.49
Return on Capital Employed				-0.92

COM:NEWENERGYCAPITAL

New Energy Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-3.74
P/B Ratio				3.24
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				54.65
EV Multiple				-2.39

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding				24.73
Operating Cycle				946.09
Cash Conversion Cycle				866.90
Asset Turnover				0.13

Metric
Operating Cash Flow				-36.94M
Free Cash Flow				-39.84M
Cash Flow to Debt				-16.61
Operating Cash Flow/Sales				-4.75
Free Cash Flow Yield				-0.18

Metric
Cash & Equivalents				16.55M
Accounts Receivable				2.88M
Inventory
Goodwill
Debt to Capitalization				0.08
Debt to Assets				0.04
Current Ratio				3.64
Quick Ratio				1.88

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.86
R&D to Revenue				10.29
SG&A to Revenue				1.03